Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy

International Journal of STD and AIDS

Volumn 16, Issue 12, 2005, Pages 807-810

  Portilla, Joaquín ^a   Boix, Vicente ^a   Garcia Henarejos, José Antonio ^b   Llopis, Coral ^a   Martínez Madrid, Onofre ^b   Gimeno, Adelina ^a   Sánchez Paya, José ^a   Merino, Esperanza ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Hospital Virgen del Rosell   (Spain)

Author keywords

Antiretroviral therapy; Clinical trial; Highly active; HIV AIDS; Nelfinavir; Saquinavir

Indexed keywords

NELFINAVIR; NUCLEOSIDE ANALOG; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; MYCOBACTERIUM INTRACELLULARE AVIUM; PATIENT SELECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMMUNOSUPPRESSION; NELFINAVIR; SAQUINAVIR; VIRAL LOAD;

EID: 30944462391     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646205774988082     Document Type: Article

References (21)

1. Bartlett J, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-77
2. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudina and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73
3. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-46
4. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis 2000;30:S177-84
5. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral therapy in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-6
6. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003;73:20-30
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7
8. Egger M, May M, Chêne G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29
9. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virologic failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000;14:141-9
10. Powderly WG, Saag MS, Chapman S, Yu G, Quart B Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999;13:1873-80
11. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286:2560-7
12. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77
13. Lichterfeld M, Nischalke HD, Bergmann F, et al. Long-term efficacy and safety of ritonavir/indinavir at 400/400mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med 2002;3:37-43
14. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126
15. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 2004;292:251-65
16. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus Indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33
17. King M, Bernstein B, Cernohous P, Moseley J, Baver E, Sun E. Impact of baseline CD4 cell count and viral load on durability of virologic response trough 96 weeks for lopinavir/ritonavir (LPV/r) and Nelfinavir (NFV) in a phase III clinical trial. Ninth Conference on Retroviruses and Opportunistic Infections (abstract no. 470). Seattle, Washington, USA, 2002
18. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998;352:185-90
19. Moyle G, Pozniak A, Opravil M, et al. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe. J Acquir Immune Defic Syndr 2000;23:128-37
20. Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998;12:F117-22
21. Reijers MH, Weigel HM, Hart AA, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000;14:59-67